Therapeutic Agent for Neuroblastoma Targeting ARID3b

Abstract

It is intended to provide a therapeutic agent for neuroblastoma. More particularly, it is intended to provide the therapeutic agent for neuroblastoma containing an ARID3b inhibitor.

1 . A composition for treating neuroblastoma, which contains an ARID3b inhibitor. 
     
     
         2 . The composition according to  claim 1 , wherein the ARID3b inhibitor is an antisense oligonucleotide or an siRNA for ARID3b mRNA. 
     
     
         3 . A method of screening for an ARID3b inhibitor, the method comprising measuring an activity of inhibiting ARID3b. 
     
     
         4 . The method according to  claim 3 , wherein the activity of inhibiting ARID3b is an activity of inhibiting expression of ARID3b. 
     
     
         5 . The method according to  claim 3 , wherein the activity of inhibiting ARID3b is an activity of inhibiting an action of ARID3b. 
     
     
         6 . A method of suppressing neuroblastoma, the method comprising inhibiting ARID3b. 
     
     
         7 . The method according to  claim 6 , wherein ARID3b is inhibited by inhibiting expression of ARID3b. 
     
     
         8 . The method according to  claim 6 , wherein ARID3b is inhibited by inhibiting an action of ARID3b. 
     
     
         9 . A method of diagnosing neuroblastoma, the method comprising measuring an expression level of ARID3b in a cell. 
     
     
         10 . The method according to  claim 9 , which further comprises measuring an expression level of MYCN in a cell. 
     
     
         11 . A cell in which expression of ARID3b is modified. 
     
     
         12 . An animal in which expression of ARID3b is modified. 
     
     
         13 . A kit for determining neuroblastoma, which contains at least an antibody against ARID3b, or an oligonucleotide that is capable of annealing to an ARID3b-encoding gene or a sequence complementary thereto. 
     
     
         14 . The kit according to  claim 13 , wherein the oligonucleotide contains a sequence of consecutive 15 to 100 nucleotides selected from an ARID3b-encoding gene or a sequence complementary thereto. 
     
     
         15 . The kit according to  claim 13 , which further contains an antibody against MYCN, or an oligonucleotide that is capable of annealing to an MYCN-encoding gene or a sequence complementary thereto.